The DOI matches its Crossref record; 110 of the 110 references it cites were found in a registry or an index.
Prodrugs: design and clinical applications
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Pharmacokinetics and pharmacodynamics of the new propofol prodrug GPI 15715 in rates
Schywalsky, M., Ihmsen, H., Tzabazis, A., Fechner, J., Burak, E. S., Vornov, J. J., & Schwilden, H. (2005) · European Journal of Anaesthesiology · doi:10.1017/s0265021503000322 · Cited by 41
RetractedAmidon, G. L., Lennernäs, H., Shah, V. P., & Crison, J. R. (1995) · Pharmaceutical Research · doi:10.1023/a:1016212804288 · Cited by 5,430
Mechanism of Oxidation Reactions Catalyzed by Cytochrome P450 Enzymes
Meunier, B., de Visser, S. P., & Shaik, S. (2004) · Chemical Reviews · doi:10.1021/cr020443g · Cited by 2,398
Common and Uncommon Cytochrome P450 Reactions Related to Metabolism and Chemical Toxicity
Guengerich, F. P. (2001) · Chemical Research in Toxicology · doi:10.1021/tx0002583 · Cited by 1,655
Miwa, M., Ura, M., Nishida, M., Sawada, N., Ishikawa, T., Mori, K., Shimma, N., Umeda, I., & Ishitsuka, H. (1998) · European Journal of Cancer · doi:10.1016/s0959-8049(98)00058-6 · Cited by 1,240
Drug interactions with lipid-lowering drugs: Mechanisms and clinical relevance
NEUVONEN, P., NIEMI, M., & BACKMAN, J. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2006.09.003 · Cited by 859
Walko, C. M., & Lindley, C. (2005) · Clinical Therapeutics · doi:10.1016/j.clinthera.2005.01.005 · Cited by 659
Property-Based Design: Optimization of Drug Absorption and Pharmacokinetics
van de Waterbeemd, H., Smith, D. A., Beaumont, K., & Walker, D. K. (2001) · Journal of Medicinal Chemistry · doi:10.1021/jm000407e · Cited by 599
Shitara, Y., & Sugiyama, Y. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2006.03.003 · Cited by 576
Prodrug strategies to overcome poor water solubility
Stella, V. J., & Nti-Addae, K. W. (2007) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.05.013 · Cited by 554
The “On–Off” Phenomenon in Parkinson’s Disease: Relation to Levodopa Absorption and Transport
Nutt, J. G., Woodward, W. R., Hammerstad, J. P., Carter, J. H., & Anderson, J. L. (1984) · New England Journal of Medicine · doi:10.1056/nejm198402233100802 · Cited by 554
Netland, P. A., Landry, T., Sullivan, E. K., Andrew, R., Silver, L., Weiner, A., Mallick, S., Dickerson, J., Bergamini, M. V. W., Robertson, S. M., et al. (2001) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(01)01177-1 · Cited by 417
Choudhuri, S., & Klaassen, C. D. (2006) · International Journal of Toxicology · doi:10.1080/10915810600746023 · Cited by 415
McComb, R. B., Bowers, G. N., & Posen, S. (1979) · Springer eBooks · doi:10.1007/978-1-4613-2970-1 · Cited by 385
Lessons Learned from Marketed and Investigational Prodrugs
Ettmayer, P., Amidon, G. L., Clement, B., & Testa, B. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm0303812 · Cited by 384
Enzymes involved in the bioconversion of ester-based prodrugs
Liederer, B. M., & Borchardt, R. T. (2006) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20542 · Cited by 377
Beaumont, K., Webster, R., Gardner, I., & Dack, K. (2003) · Current Drug Metabolism · doi:10.2174/1389200033489253 · Cited by 363
Role of pharmacogenetics of ATP-binding cassette transporters in the pharmacokinetics of drugs
Cascorbi, I. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2006.04.009 · Cited by 355
Boxenbaum, H. (1980) · Journal of Pharmacokinetics and Biopharmaceutics · doi:10.1007/bf01065191 · Cited by 347
Brogden, R. N., Todd, P. A., & Sorkin, E. M. (1988) · Drugs · doi:10.2165/00003495-198836050-00003 · Cited by 318
Transport of Valganciclovir, a Ganciclovir Prodrug, via Peptide Transporters PEPT1 and PEPT2
Sugawara, M., Huang, W., Fei, Y., Leibach, F. H., Ganapathy, V., & Ganapathy, M. E. (2000) · Journal of Pharmaceutical Sciences · doi:10.1002/(sici)1520-6017(200006)89:6<781::aid-jps10>3.0.co;2-7 · Cited by 312
Slatter, J. G., Schaaf, L. J., Sams, J. P., Feenstra, K. L., Johnson, M. G., Bombardt, P. A., Cathcart, K. S., Verburg, M. T., Pearson, L. K., Compton, L. D., et al. (2000) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15060-x · Cited by 302
Han, H.-K., de Vrueh, R. L. A., Rhie, J. K., Covitz, K.-M. Y., Smith, P. L., Lee, C.-P., Oh, D.-M., Sadee, W., & Amidon1, G. L. (1998) · Pharmaceutical Research · doi:10.1023/a:1011919319810 · Cited by 297
Self-citationShi, D., Yang, J., Yang, D., LeCluyse, E. L., Black, C., Li, Y., Akhlaghi, F., & Yan, B. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.111807 · Cited by 279
Targeted prodrug design to optimize drug delivery
Han, H.-K., & Amidon, G. L. (2000) · AAPS PharmSci · doi:10.1208/ps020106 · Cited by 277
Todd, P. A., & Heel, R. C. (1986) · Drugs · doi:10.2165/00003495-198631030-00002 · Cited by 270
Oseltamivir: A Review of its Use in Influenza
McClellan, K., & Perry, C. M. (2001) · Drugs · doi:10.2165/00003495-200161020-00011 · Cited by 257
Perry, C. M., & Faulds, D. (1996) · Drugs · doi:10.2165/00003495-199652050-00009 · Cited by 240
Soft drug design: General principles and recent applications
Bodor, N., & Buchwald, P. (2000) · Medicinal Research Reviews · doi:10.1002/(sici)1098-1128(200001)20:1<58::aid-med3>3.0.co;2-x · Cited by 239
Rationale for Design of Biologically Reversible Drug Derivatives: Prodrugs
Sinkula, A. A., & Yalkowsky, S. H. (1975) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600640203 · Cited by 223
Drug Uptake Systems in Liver and Kidney
van Montfoort, J., Hagenbuch, B., Groothuis, G., Koepsell, H., Meier, P., & Meijer, D. (2003) · Current Drug Metabolism · doi:10.2174/1389200033489460 · Cited by 221
Balimane, P. V., Tamai, I., Guo, A., Nakanishi, T., Kitada, H., Leibach, F. H., Tsuji, A., & Sinko, P. J. (1998) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1998.9298 · Cited by 214
(2001) · Wiley eBooks · doi:10.1002/9783906390437 · Cited by 212
Vere Hodge, R. A., Sutton, D., Boyd, M. R., Harnden, M. R., & Jarvest, R. L. (1989) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.33.10.1765 · Cited by 210
Clinical Pharmacokinetics and Practical Applications of Simvastatin
Mauro, V. F. (1993) · Clinical Pharmacokinetics · doi:10.2165/00003088-199324030-00002 · Cited by 188
Quinney, S. K., Sanghani, S. P., Davis, W. I., Hurley, T. D., Sun, Z., Murry, D. J., & Bosron, W. F. (2005) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.081265 · Cited by 184
Tazarotene-first of a new generation of receptor-selective retinoids
CHANDRARATNA, R. A. S. (1996) · British Journal of Dermatology · doi:10.1111/j.1365-2133.1996.tb15662.x · Cited by 172
The road map to oral bioavailability: an industrial perspective
Thomas, V. H., Bhattachar, S., Hitchingham, L., Zocharski, P., Naath, M., Surendran, N., Stoner, C. L., & El-Kattan, A. (2006) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2.4.591 · Cited by 168
Intestinal Peptide Transport Systems and Oral Drug Availability
Yang, C. Y., Dantzig, A. H., & Pidgeon, C. (1999) · Pharmaceutical Research · doi:10.1023/a:1018982505021 · Cited by 166
Erion, M. D., Reddy, K. R., Boyer, S. H., Matelich, M. C., Gomez-Galeno, J., Lemus, R. H., Ugarkar, B. G., Colby, T. J., Schanzer, J., & van Poelje, P. D. (2004) · Journal of the American Chemical Society · doi:10.1021/ja031818y · Cited by 165
Francis, R. J., Sharma, S. K., Springer, C., Green, A. J., Hope-Stone, L. D., Sena, L., Martin, J., Adamson, K. L., Robbins, A., Gumbrell, L., et al. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600517 · Cited by 163
Gallant, J. E., & Deresinski, S. (2003) · Clinical Infectious Diseases · doi:10.1086/378068 · Cited by 162
Sharif, N. A., Kelly, C. R., Crider, J. Y., Williams, G. W., & Xu, S. X. (2003) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/108076803322660422 · Cited by 162
Structural insights into CPT-11 activation by mammalian carboxylesterases
Bencharit, S., Morton, C. L., Howard-Williams, E. L., Danks, M. K., Potter, P. M., & Redinbo, M. R. (2002) · Nature Structural Biology · doi:10.1038/nsb790 · Cited by 161
Prodrugs : challenges and rewards
Stella, V. J. (2007) · Cited by 153
Eriksson, U. G., Bredberg, U., Hoffmann, K., Thuresson, A., Gabrielsson, M., Ericsson, H., Ahnoff, M., Gislén, K., Fager, G., & Gustafsson, D. (2003) · Drug Metabolism and Disposition · doi:10.1124/dmd.31.3.294 · Cited by 153
Slatter, J. G., Su, P., Sams, J. P., Schaaf, L. J., & Wienkers, L. C. (1997) · PubMed · Cited by 152
Cundy, K. C., Branch, R., Chernov-Rogan, T., et al. (2004) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.067934 · Cited by 152
Carboxylesterases - Detoxifying Enzymes and Targets for Drug Therapy
Potter, P. M., & Wadkins, R. M. (2006) · Current Medicinal Chemistry · doi:10.2174/092986706776360969 · Cited by 150
Levodopa pharmacokinetics and pharmacodynamics in fluctuating parkinsonian patients
Nutt, J. G., & Woodward, W. R. (1986) · Neurology · doi:10.1212/wnl.36.6.739 · Cited by 149
Irinotecan (CPT-11): Recent Developments and Future Directions–Colorectal Cancer and Beyond
Rothenberg, M. L. (2001) · The Oncologist · doi:10.1634/theoncologist.6-1-66 · Cited by 146
Sanghani, S. P., Quinney, S. K., Fredenburg, T. B., Davis, W. I., Murry, D. J., & BOSRON, W. F. (2004) · Drug Metabolism and Disposition · doi:10.1124/dmd.32.5.505 · Cited by 145
Guichard, S. M., Terret, C., Hennebelle, I., Lochon, I., Chevreau, P., Frétigny, E., Sèlves, J., Chatelut, É., Bugat, R., & Canal, P. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690364 · Cited by 142
Pharmacology and pharmacokinetics of fosphenytoin
Browne, T. R., Kugler, A. R., & Eldon, M. A. (1996) · Neurology · doi:10.1212/wnl.46.6_suppl_1.3s · Cited by 136
Pivalate-Generating Prodrugs and Carnitine Homeostasis in Man
Brass, E. P. (2002) · Pharmacological Reviews · doi:10.1124/pr.54.4.589 · Cited by 136
Prevalence of atopic eczema in the community: the Lothian Atopic Dermatitis study.
Herd, R. M., Tidman, M. J., Prescott, R. J., & Hunter, J. A. A. (1996) · PubMed · Cited by 135
Intestinal solute carriers: an overview of trends and strategies for improving oral drug absorption
Steffansen, B., Nielsen, C. U., Brodin, B., Eriksson, A. H., Andersen, R., & Frøkjær, S. (2003) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2003.10.010 · Cited by 132
Stella, V. J., Tilley, J., Oliyai, R., Maag, H., Hageman, M. J., & Borchardt, R. T. (2007) · Springer eBooks · doi:10.1007/978-0-387-49785-3 · Cited by 131
Self-citationde Groot, F. M. H., Damen, E. W. P., & Scheeren, H. W. (2001) · Current Medicinal Chemistry · doi:10.2174/0929867013372634 · Cited by 129
Antibody-directed enzyme prodrug therapy: efficacy and mechanism of action in colorectal carcinoma.
Napier, M. P., Sharma, S., Springer, C. J., et al. (2000) · PubMed · Cited by 128
Wire, M. B., Shelton, M. J., & Studenberg, S. D. (2006) · Clinical Pharmacokinetics · doi:10.2165/00003088-200645020-00002 · Cited by 127
Prodrug research: futile or fertile?
Testa, B. (2004) · Biochemical Pharmacology · doi:10.1016/j.bcp.2004.07.005 · Cited by 124
Cundy, K. C., Annamalai, T., Bu, L., et al. (2004) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.067959 · Cited by 121
Liver-Targeted Drug Delivery Using HepDirect Prodrugs
Erion, M. D., van Poelje, P. D., MacKenna, D. A., Colby, T. J., Montag, A. C., Fujitaki, J. M., Linemeyer, D. L., & Bullough, D. A. (2005) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.075903 · Cited by 119
REDUCTION OFN-HYDROXYLATED COMPOUNDS: AMIDOXIMES (N-HYDROXYAMIDINES) AS PRO-DRUGS OF AMIDINES
Clement, B. (2002) · Drug Metabolism Reviews · doi:10.1081/dmr-120005643 · Cited by 119
Intramuscular Preparations of Antipsychotics: Uses and Relevance in Clinical Practice
Altamura, A. C., Sassella, F., Santini, A., Montresor, C., Fumagalli, S., & Mundo, E. (2003) · Drugs · doi:10.2165/00003495-200363050-00004 · Cited by 117
From bench to bedside for gene-directed enzyme prodrug therapy of cancer
Dachs, G. U., Tupper, J., & Tozer, G. M. (2005) · Anti-Cancer Drugs · doi:10.1097/00001813-200504000-00001 · Cited by 113
Sinhababu, A. K., & Thakker, D. R. (1996) · Advanced Drug Delivery Reviews · doi:10.1016/0169-409x(95)00109-k · Cited by 105
Oral bioavailability and first-pass effects.
Kwan, K. C. (1997) · PubMed · Cited by 104
Chapman, T. M., McGavin, J. K., & Noble, S. (2003) · Drugs · doi:10.2165/00003495-200363150-00006 · Cited by 103
Jousserandot, A., Boucher, J., Henry, Y. A., Niklaus, B., Clement, B., & Mansuy, D. (1998) · Biochemistry · doi:10.1021/bi981175c · Cited by 93
Gene-Directed Enzyme Prodrug Therapy
Niculescu‐Duvaz, I., Spooner, R. A., Marais, R., & Springer, C. J. (1998) · Bioconjugate Chemistry · doi:10.1021/bc970116t · Cited by 92
de Vrueh, R. L. A., Smith, P. L., & Lee, C. (1998) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37707-9 · Cited by 91
Clement, B., & Lopian, K. (2003) · Drug Metabolism and Disposition · doi:10.1124/dmd.31.5.645 · Cited by 90
Perry, C. M., & McTavish, D. (1995) · Drugs & Aging · doi:10.2165/00002512-199507010-00006 · Cited by 88
Stella, V. J. (2004) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.14.3.277 · Cited by 87
Minto, C. F., Howe, C., Wishart, S. M., Conway, A. J., & Handelsman, D. J. (1997) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)36598-x · Cited by 83
Antibody-directed enzyme prodrug therapy (ADEPT) for cancer
Bagshawe, K. D., Sharma, S. K., & Beǵent, R. H. J. (2004) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.4.11.1777 · Cited by 81
Designing for topical delivery: Prodrugs can make the difference
Sloan, K. B., & Wasdo, S. C. (2003) · Medicinal Research Reviews · doi:10.1002/med.10048 · Cited by 79
Absorption Rate Limit Considerations for Oral Phosphate Prodrugs
Heimbach, T., Oh, D.-M., Li, L. Y., Forsberg, M., Savolainen, J., Leppänen, J., Matsunaga, Y., Flynn, G. L., & Fleisher, D. (2003) · Pharmaceutical Research · doi:10.1023/a:1023827017224 · Cited by 79
Self-citationTissue selectivity of hydroxymethylglutaryl coenzyme a (HMG CoA) reductase inhibitors
Sirtori, C. R. (1993) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(93)90031-8 · Cited by 77
Brogden, R. N., & Faulds, D. M. (1995) · Drugs & Aging · doi:10.2165/00002512-199506040-00007 · Cited by 77
Bardsley-Elliot, A., & Noble, S. (1999) · Drugs · doi:10.2165/00003495-199958050-00007 · Cited by 77
Simpson, D., & Lyseng-Williamson, K. A. (2006) · Drugs · doi:10.2165/00003495-200666180-00016 · Cited by 74
The design and bioactivation of presystemically stable prodrugs
Svensson, L.-Å., & Tunek, A. (1988) · Drug Metabolism Reviews · doi:10.3109/03602538809049622 · Cited by 73
Gad, S. C. (1994) · Cited by 65
Prodrugs for improved CNS delivery
Anderson, B. D. (1996) · Advanced Drug Delivery Reviews · doi:10.1016/0169-409x(95)00106-h · Cited by 65
Prodrug based optimal drug delivery via membrane transporter/receptor
Yang, C., Tirucherai, G., & Mitra, A. K. (2001) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.1.2.159 · Cited by 64
Improved passive oral drug delivery via prodrugs
Taylor, M. D. (1996) · Advanced Drug Delivery Reviews · doi:10.1016/0169-409x(95)00104-f · Cited by 62
Prodrugs for improved ocular drug delivery
Järvinen, T., & Järvinen, K. (1996) · Advanced Drug Delivery Reviews · doi:10.1016/0169-409x(95)00107-i · Cited by 62
Self-citationTsuda, M., Terada, T., Irie, M., Katsura, T., Niida, A., Tomita, K., Fujii, N., & Inui, K. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.102830 · Cited by 61
Reusser, P. (2001) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.10.9.1745 · Cited by 60
Piperazinylalkyl prodrugs of naproxen improve in vitro skin permeation
Rautio, J., Nevalainen, T., Taipale, H., et al. (2000) · European Journal of Pharmaceutical Sciences · doi:10.1016/s0928-0987(00)00090-7 · Cited by 60
Self-citationThorsteinsson, T., Loftsson, Þ., & Másson, M. (2003) · Current Medicinal Chemistry · doi:10.2174/0929867033457520 · Cited by 60
Oseltamivir: a clinical and pharmacological perspective
Aoki, F. Y., & Doucette, K. E. (2001) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2.10.1671 · Cited by 60
Role of efflux pumps and metabolising enzymes in drug delivery
Katragadda, S., Budda, B., Anand, B. S., & Mitra, A. K. (2005) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2.4.683 · Cited by 58
Drug targeting via retrometabolic approaches
Bodor, N. S., & Buchwald, P. (1997) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(97)00098-3 · Cited by 57
Hellberg, M. R., Ke, T.-L., Haggard, K. S., Klimko, P. G., Dean, T. R., & Graff, G. (2003) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/108076803321637627 · Cited by 50
Simvastatin: A Review of its Pharmacology and Clinical Use
Mauro, V. F., & MacDonald, J. L. (1991) · DICP · doi:10.1177/106002809102500309 · Cited by 47
Enhancement of transdermal delivery of 6-β-naltrexol via a codrug linked to hydroxybupropion
Kiptoo, P. K., Hamad, M. O., Crooks, P. A., & Stinchcomb, A. L. (2006) · Journal of Controlled Release · doi:10.1016/j.jconrel.2006.04.003 · Cited by 46
Bentley, A., Butters, M., Green, S. P., Learmonth, W. J., MacRae, J., Morland, M. C., O'Conno, G., & Skuse, J. (2001) · Organic Process Research & Development · doi:10.1021/op010064+ · Cited by 44
Midodrine: a selective α-adrenergic agonist for orthostatic hypotension and dialysis hypotension
Cruz, D. N. (2000) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.1.4.835 · Cited by 44
Yasuhara, A., Nakamura, M., Sakagami, K., Shimazaki, T., Yoshikawa, R., Chaki, S., Ohta, H., & Nakazato, A. (2006) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2006.01.060 · Cited by 43
Prediction of gastro-intestinal absorption using multivariate adaptive regression splines
Deconinck, E., Xu, Q., Put, R., et al. (2005) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2005.05.034 · Cited by 37
Pharmacokinetics and Pharmacodynamics of Estramustine Phosphate
Bergenheim, A. T., & Henriksson, R. (1998) · Clinical Pharmacokinetics · doi:10.2165/00003088-199834020-00004 · Cited by 32
Advances in antibody-directed enzyme prodrug therapy.
Sharma, S. K., Bagshawe, K. D., & Beǵent, R. H. J. (2005) · PubMed · Cited by 32
Intestinal drug absorption and bioavailability: beyond involvement of single transport function
Lennernäs, H. (2003) · Journal of Pharmacy and Pharmacology · doi:10.1211/002235702973 · Cited by 28
Russell, J. W., Marrero, D., Whiterock, V. J., et al. (1991) · Journal of Chromatography B Biomedical Sciences and Applications · doi:10.1016/0378-4347(91)80498-2 · Cited by 19
Nakamura, M., Kawakita, Y., Yasuhara, A., Fukasawa, Y., Yoshida, K., Sakagami, K., & Nakazato, A. (2005) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.006213 · Cited by 14
Prodrug approaches to ophthalmic drug delivery
Järvinen, T., & Niemi, R. (2007) · Springer eBooks · doi:10.1007/978-0-387-49785-3_4 · Cited by 10
Self-citation
Cited by
The Medicinal Chemist’s Toolbox: An Analysis of Reactions Used in the Pursuit of Drug Candidates
Roughley, S. D., & Jordan, A. M. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200187y · Cited by 2,725
Biological Activity of Ionic Liquids and Their Application in Pharmaceutics and Medicine
Egorova, K. S., Gordeev, E. G., & Ananikov, V. P. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.6b00562 · Cited by 1,649
Artificial intelligence to deep learning: machine intelligence approach for drug discovery
Gupta, R., Srivastava, D., Sahu, M., Tiwari, S., Ambasta, R. K., & Kumar, P. (2021) · Molecular Diversity · doi:10.1007/s11030-021-10217-3 · Cited by 1,473
“…with a small number of people; Phase 2, drug efficacy testing with the small number of human subjects affected by a particular disease; Phase 3, efficacy studies with a large number of patients and after passing the clinical trials FDA reviews it for approval and commercialization [451, 452].”
BackgroundGaudana, R., Ananthula, H. K., Parenky, A., & Mitra, A. K. (2010) · The AAPS Journal · doi:10.1208/s12248-010-9183-3 · Cited by 1,406
Microbial siderophores and their potential applications: a review
Saha, M., Sarkar, S., Sarkar, B., Sharma, B. K., Bhattacharjee, S., & Tribedi, P. (2016) · Environmental Science and Pollution Research · doi:10.1007/s11356-015-4294-0 · Cited by 819
Metadata
- Authors
- Rautio, J., Kumpulainen, H., Heimbach, T., Oliyai, R., Oh, D., Järvinen, T., & Savolainen, J.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2008-03
- Volume
- 7
- Issue
- 3
- Pages
- 255-270
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2059183805
- Cited by
- 1,630
- References
- 110
- FWCI
- 2.69
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.